Shots:
- GSK has reported global P-II (AZUR-1) trial data assessing Jemperli (dostarlimab) (500mg, IV, Q3W for 9 cycles) in 154 pts with stage II/III mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) locally advanced rectal cancer
- Trial met its 1EP, with a meaningful & sustained clinical complete response rate at 12mos. Interim AZUR-1 data will be shared with global regulatory authorities to support review, incl. accelerated review in the US, & presented at a future congress
- Jemperli is a PD-1-blocking antibody discovered by AnaptysBio & licensed to TESARO in 2014, with GSK responsible for its ongoing research, development, manufacturing, & commercialization
Ref: GSK | Image: GSK | Press Release
Related News: GSK & Spero Therapeutics Report the US FDA Approval of Utebzi for Complicated Urinary Tract Infections (cUTIs)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
